Repositioning Candidate Details
| Candidate ID: | R0980 |
| Source ID: | DB06323 |
| Source Type: | investigational |
| Compound Type: | biotech |
| Compound Name: | AZX-100 |
| Synonyms: | -- |
| Molecular Formula: | -- |
| SMILES: | -- |
| DrugBank Description: | -- |
| CAS Number: | 1217194-46-1 |
| Molecular Weight: | |
| DrugBank Indication: | Investigated for use/treatment in scar tissue. |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | AZX100 is a synthetic 24 amino acid peptide in the field of smooth muscle relaxation and fibrosis. Signaling pathways for actin-mediated smooth muscle relaxation converge by activating a protein called heat shock related protein 20 (HSP20). AZX-100 is a cell permeant peptide that mimics HSP20, bypassing the signaling pathways leading to smooth muscle relaxation. This mechanism of action is particularly important in certain patients, such as asthmatics with mutations in the β-receptor (β16 Arg/Arg genotype) or in some forms of vasospasm (such as subarachnoid hemorrhage induced vasospasm which leads to strokes). |
| Targets: | -- |
| Inclusion Criteria: | Therapeutic strategy associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S03 | Anti-fibrosis | fibrosis | Angiotensin Receptor Blocker (ARB); CCR2/CCR5 antagonist; Thyroid receptor β agonist; PEGylated human FGF21 analogue; Monoclonal antibody to lysyl oxidase-like 2 (LOXL2); Galectin-3 inhibitor; FGF19 variant | Losartan; Cenicriviroc; VK-2809; MGL-3196; Pegbelfermin; Simtuzumab; GR-MD-02; NGM282 | Details |
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I16 | 6713 | Cerebrovascular disease | An vascular disease that is characterized by dysfunction of the blood vessels supplying the brain. http://en.wikipedia.org/wiki/Cerebrovascular_disease, http://www.ncbi.nlm.nih.gov/books/NBK378/ | disease of anatomical entity/ cardiovascular system disease/ vascular disease/cerebrovascular disease | Details |